GTN Ltd.

GTN aims to solve the difficulty in getting treatments for neurological diseases into the brain due to the blood-brain barrier. The idea is for machine learning to come up with compounds that a chemist may not think of that has the ability to cross the blood-brain barrier.

CEO Noor Shaker was an assistant professor at Aalborg University, Copenhagen and worked on machine learning. Shaker and GTN were named in the top 100 AI Leaders in Drug and Discovery and Advanced Healthcare by Deep Knowledge Analytics in 2019. In 2018 she was listed at one of the top 30 women leaders in UK healthcare.

Shaker, with expertise in artificial intelligence and Stojevic a theoretical physicist with quantum physics expertise, joined forces in 2016 at the London-based accelerator, Entrepreneur First. CTO Vid Stojevic co-authored a paper on hierarchical quantum classifiers in Nature Quantum Information in 2018.

GTN is one of the startups collaborating with Microsoft in the Microsoft Quantum Team.